Phase 1 Endometrial Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women who are at least 18 years old, have their uterus and cervix still in place, and have been diagnosed with cervical cancer (confirmed by tissue testing) at an early stage (less than FIGO stage IB3) that is planned to be treated with standard surgery
• People who are not pregnant, not breastfeeding, and either cannot become pregnant or agree to follow the trial's contraception guidelines from the start of treatment until at least the time of their scheduled surgery
• People who are willing and able to provide written consent to take part in the trial (or have a legal representative do so on their behalf)

Who may not be able to join:

• People who could become pregnant and have a positive pregnancy test within 72 hours before being allocated to the trial
• People who have previously been treated with certain immune checkpoint therapies, including anti-PD-1, anti-PD-L1, anti-PD-L2, or similar drugs that target T-cell receptors (such as those targeting CTLA-4, OX40, or CD137)
• People who have received any systemic anti-cancer treatment, including experimental treatments, within 4 weeks before being allocated to the trial
• People who have had radiotherapy within 2 weeks before starting the study treatment, or who still have side effects from radiation, or who needed steroids after radiation, or who had radiation-related lung problems (a shorter 1-week gap may apply for certain limited palliative radiation to areas outside the brain)
• People who have received a live vaccine within 30 days before the first dose of study treatment — this includes vaccines for measles, mumps, rubella, chickenpox, yellow fever, rabies, BCG, and some typhoid and nasal flu vaccines (injected seasonal flu vaccines are generally allowed)
• People who are currently in another clinical trial or have used an experimental treatment or device within 4 weeks before the first dose of study treatment
• People who have an immune system deficiency, or who are taking high-dose steroid medications (more than 10 mg of prednisone or equivalent per day) or other immune-suppressing medications within 7 days before the first dose of study treatment
• People who have another cancer that is currently active or has required treatment within the past 3 years (people with certain skin cancers or early-stage cancers that have been successfully treated may still be considered — confirm with trial site)
• People who have active cancer spread to the brain or the membranes surrounding the brain or spinal cord
• People who have had a severe allergic reaction (Grade 3 or higher) to nivolumab or any of its ingredients
• People who have an autoimmune disease that has required systemic medical treatment within the past 2 years (hormone or gland replacement therapies are not considered systemic treatment for this purpose)
• People who have a history of lung inflammation (pneumonitis) that required steroid treatment, or who currently have pneumonitis
• People who have an active infection that requires systemic treatment
• People for whom an MRI scan is not safe or possible — for example, due to certain implanted devices such as pacemakers, cochlear implants, or neurostimulators, metal fragments in the body, or severe claustrophobia that cannot be managed
• People who have had surgery in the groin area that may have affected the lymphatic drainage in that region
• People with a known history of HIV (confirm with trial site regarding local testing requirements)
• People with a known history of active Hepatitis B or active Hepatitis C infection (confirm with trial site regarding local testing requirements)
• People with any medical condition, previous treatment, or abnormal test results that the treating doctor believes could affect the study results, interfere with full participation, or make participation not in the person's best interest
• People with known psychiatric conditions or substance use disorders that would make it difficult to follow the trial requirements
• People who are pregnant, breastfeeding, or planning to become pregnant during the study period, from the screening visit through 120 days after the last dose of trial treatment
• People who, in the judgment of the research doctor or medical oncologist, are considered unsuitable for the trial for any reason, including poor general health, abnormal test results, or other medical or personal factors that could affect safety or the quality of the study

Important: Always verify eligibility with the trial site directly before applying.